HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Upjohn Caverject injection for erectile dysfunction to reach pharmacy shelves by August.

Executive Summary

UPJOHN CAVERJECT TO REACH PHARMACY SHELVES BY LATE AUGUST following FDA marketing approval July 6. Alprostadil sterile powder is indicated for the diagnosis and treatment of male erectile dysfunction due to neurologic, vascular, psychological or mixed causes. "Caverject may be a useful adjunct to other diagnostic tests in the diagnosis of erectile dysfunction," labeling adds. Caverject is the first prescription medication for erectile dysfunction approved in the U.S. The NDA for Caverject was filed in February 1994.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026504

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel